Text Size

Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever

This study has been completed.
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01034059
First received: December 16, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted
  Purpose

The soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) was an established biomarker useful for infection in non-neutropenic patients. In this study, we tested sTREM-1 in the patients with neutropenic fever. Pro-calcitonin (PCT) and C-reactive protein (CRP) were also measured. We planned to investigate and explore the role of sTREM-1 in early diagnosis of infection in patients with neutropenic fever.


Condition
Neutropenic Fever

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever

Resource links provided by NLM:

MedlinePlus related topics: Fever
U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:

Biospecimen Retention:   Samples With DNA

whole blood


Enrollment: 75
Study Start Date: October 2008
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Detailed Description:

Patients with hematological malignancies developed neutropenia after chemotherapy. We checked the serum level of sTREM-1 in patients with neutropenic fever. Those patients were classified to 2 groups: documented infection or low likelihood of infection. Their sTREM-1 level was measured and was compared with other biomarker such as CRP and procalcitonin. The value of sTREM-1 for diagnosis of infection in patients with neutropenic fever was thus evaluated.

  Eligibility

Ages Eligible for Study:   18 Years to 84 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with hematological malignancy developing neutropenic fever after chemotherapy

Criteria

Inclusion Criteria:

  • chemotherapy-related neutropenia (granulocytes < 0.5 × 109/l or leukocytes < 1 × 109/l) and fever (body temperature > 38.0°C over a 6 hour observation period or body temperature ≥ 38.5°C once.

Exclusion Criteria:

  • prolonged fever before presenting for admission,
  • antibiotics therapy in the past 72 hours,
  • more than two sites of infectious focus,
  • concomitant solid organ malignancy and blast in hemogram.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01034059

Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Szu-Chun Hsu, MD Department of Laboratory Medicine, National Taiwan University Hospital and College of Medicine, Taipei
  More Information

No publications provided

Responsible Party: Szu-Chun Hsu, Department of Laboratory Medicine, National Taiwan University Hospital and College of Medicine, Taipei
ClinicalTrials.gov Identifier: NCT01034059     History of Changes
Other Study ID Numbers: 200806051R
Study First Received: December 16, 2009
Last Updated: December 16, 2009
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Fever
Neutropenia
Body Temperature Changes
Signs and Symptoms
 Agranulocytosis
Leukopenia
Leukocyte Disorders
Hematologic Diseases

ClinicalTrials.gov processed this record on June 18, 2013